{"entity":{"type":"insider","cik":"0001544443","url":"/insider/0001544443","json_url":"/insider/0001544443.json","name":"ARCH Venture Partners VII, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":28,"n_filings":13,"first":"2013-05-14","last":"2025-10-29","span_basis":"filed_date"},"name_variants":[{"name":"ARCH Venture Partners VII, LLC","source":"filing","n_filings":13,"first_seen":"2013-05-14","last_seen":"2025-10-29"}],"transactions":[{"id":5119195,"accession":"0001012975-25-000679","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-25-000679","line_url":"/filing/0001012975-25-000679#line-1","is_derivative":false,"issuer_cik":"0001402439","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001402439","owner_cik":null,"owner_name":"ARCH Venture Fund X, L.P.; ARCH Venture Fund VII, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners VIII, LLC","owner_display_name":"ARCH Venture Fund X, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1915700.0,"shares_display":"1,915,700","price_per_share":2.61,"price_display":"2.61","price_state":"stated","total_value":4999977.0,"total_display":"4,999,977.00","total_whole":"4,999,977","shares_owned_after":6046907.0,"shares_owned_after_display":"6,046,907","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-27","filed_date":"2025-10-29","scope":"insider"},{"id":7915440,"accession":"0000899243-23-019273","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-23-019273","line_url":"/filing/0000899243-23-019273#line-6","is_derivative":false,"issuer_cik":"0001402439","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001402439","owner_cik":null,"owner_name":"ARCH Venture Fund VII, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund X Overage, L.P.","owner_display_name":"ARCH Venture Fund VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":25500000.0,"total_display":"25,500,000.00","total_whole":"25,500,000","shares_owned_after":3624143.0,"shares_owned_after_display":"3,624,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-20","scope":"insider"},{"id":2425253,"accession":"0001104659-20-138752","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-20-138752","line_url":"/filing/0001104659-20-138752#line-2","is_derivative":false,"issuer_cik":"0001219042","issuer_name":"908 Devices Inc.","issuer_ticker":"MASS","issuer_name_source":null,"issuer_url":"/issuer/0001219042","owner_cik":null,"owner_name":"ARCH Venture Partners VII, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Fund VII, L.P.; NELSEN ROBERT; BYBEE CLINTON","owner_display_name":"ARCH Venture Partners VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":6000000.0,"total_display":"6,000,000.00","total_whole":"6,000,000","shares_owned_after":5725045.0,"shares_owned_after_display":"5,725,045","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-22","filed_date":"2020-12-22","scope":"insider"},{"id":8581304,"accession":"0001012975-19-000489","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-19-000489","line_url":"/filing/0001012975-19-000489#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; ARCH Venture Fund VII, L.P.; BYBEE CLINTON; ARCH Venture Partners VII, LLC; NELSEN ROBERT; ARCH Venture Partners VII, L.P.","owner_display_name":"CRANDELL KEITH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34521.0,"shares_display":"34,521","price_per_share":7.6964,"price_display":"7.70","price_state":"stated","total_value":265687.4244,"total_display":"265,687.42","total_whole":"265,687","shares_owned_after":4242051.0,"shares_owned_after_display":"4,242,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-17","filed_date":"2019-07-17","scope":"insider"},{"id":8581303,"accession":"0001012975-19-000489","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-19-000489","line_url":"/filing/0001012975-19-000489#line-2","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; ARCH Venture Fund VII, L.P.; BYBEE CLINTON; ARCH Venture Partners VII, LLC; NELSEN ROBERT; ARCH Venture Partners VII, L.P.","owner_display_name":"CRANDELL KEITH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25779.0,"shares_display":"25,779","price_per_share":7.8078,"price_display":"7.81","price_state":"stated","total_value":201277.2762,"total_display":"201,277.28","total_whole":"201,277","shares_owned_after":4276572.0,"shares_owned_after_display":"4,276,572","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-16","filed_date":"2019-07-17","scope":"insider"},{"id":8581302,"accession":"0001012975-19-000489","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-19-000489","line_url":"/filing/0001012975-19-000489#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; ARCH Venture Fund VII, L.P.; BYBEE CLINTON; ARCH Venture Partners VII, LLC; NELSEN ROBERT; ARCH Venture Partners VII, L.P.","owner_display_name":"CRANDELL KEITH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2700.0,"shares_display":"2,700","price_per_share":8.2651,"price_display":"8.27","price_state":"stated","total_value":22315.77,"total_display":"22,315.77","total_whole":"22,316","shares_owned_after":4302051.0,"shares_owned_after_display":"4,302,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-15","filed_date":"2019-07-17","scope":"insider"},{"id":8612907,"accession":"0001012975-19-000242","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001012975-19-000242","line_url":"/filing/0001012975-19-000242#line-4","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"BYBEE CLINTON; ARCH Venture Partners VII, L.P.; ARCH Venture Fund VII, L.P.; CRANDELL KEITH; ARCH Venture Partners VII, LLC; NELSEN ROBERT","owner_display_name":"BYBEE CLINTON","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":43000.0,"shares_display":"43,000","price_per_share":8.1498,"price_display":"8.15","price_state":"stated","total_value":350441.4,"total_display":"350,441.40","total_whole":"350,441","shares_owned_after":4305051.0,"shares_owned_after_display":"4,305,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-14","filed_date":"2019-03-14","scope":"insider"},{"id":8612904,"accession":"0001012975-19-000242","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-19-000242","line_url":"/filing/0001012975-19-000242","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"BYBEE CLINTON; ARCH Venture Partners VII, L.P.; ARCH Venture Fund VII, L.P.; CRANDELL KEITH; ARCH Venture Partners VII, LLC; NELSEN ROBERT","owner_display_name":"BYBEE CLINTON","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":84411.0,"shares_display":"84,411","price_per_share":7.8966600348295835,"price_display":"7.90","price_state":"stated","total_value":666564.9702,"total_display":"666,564.97","total_whole":"666,565","shares_owned_after":4350871.0,"shares_owned_after_display":"4,350,871","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-13","filed_date":"2019-03-14","scope":"insider","n_lines":2},{"id":8612899,"accession":"0001012975-19-000242","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-19-000242","line_url":"/filing/0001012975-19-000242#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"BYBEE CLINTON; ARCH Venture Partners VII, L.P.; ARCH Venture Fund VII, L.P.; CRANDELL KEITH; ARCH Venture Partners VII, LLC; NELSEN ROBERT","owner_display_name":"BYBEE CLINTON","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40092.0,"shares_display":"40,092","price_per_share":7.3674,"price_display":"7.37","price_state":"stated","total_value":295373.8008,"total_display":"295,373.80","total_whole":"295,374","shares_owned_after":4432462.0,"shares_owned_after_display":"4,432,462","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-12","filed_date":"2019-03-14","scope":"insider"},{"id":8508919,"accession":"0001012975-19-000225","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-19-000225","line_url":"/filing/0001012975-19-000225#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners VII, LLC; ARCH Venture Partners VII, L.P.; BYBEE CLINTON; ARCH Venture Fund VII, L.P.; NELSEN ROBERT; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners VII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44878.0,"shares_display":"44,878","price_per_share":6.4924,"price_display":"6.49","price_state":"stated","total_value":291365.9272,"total_display":"291,365.93","total_whole":"291,366","shares_owned_after":4472554.0,"shares_owned_after_display":"4,472,554","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-11","filed_date":"2019-03-11","scope":"insider"},{"id":8508915,"accession":"0001012975-19-000225","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-19-000225","line_url":"/filing/0001012975-19-000225#line-2","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners VII, LLC; ARCH Venture Partners VII, L.P.; BYBEE CLINTON; ARCH Venture Fund VII, L.P.; NELSEN ROBERT; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners VII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":84496.0,"shares_display":"84,496","price_per_share":6.9266,"price_display":"6.93","price_state":"stated","total_value":585269.9936,"total_display":"585,269.99","total_whole":"585,270","shares_owned_after":4517432.0,"shares_owned_after_display":"4,517,432","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-08","filed_date":"2019-03-11","scope":"insider"},{"id":8508912,"accession":"0001012975-19-000225","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-19-000225","line_url":"/filing/0001012975-19-000225#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners VII, LLC; ARCH Venture Partners VII, L.P.; BYBEE CLINTON; ARCH Venture Fund VII, L.P.; NELSEN ROBERT; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners VII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35209.0,"shares_display":"35,209","price_per_share":6.8736,"price_display":"6.87","price_state":"stated","total_value":242012.5824,"total_display":"242,012.58","total_whole":"242,013","shares_owned_after":4601928.0,"shares_owned_after_display":"4,601,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-07","filed_date":"2019-03-11","scope":"insider"},{"id":6040042,"accession":"0001012975-18-001198","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001012975-18-001198","line_url":"/filing/0001012975-18-001198","is_derivative":false,"issuer_cik":"0001219042","issuer_name":"Twist Bioscience Corp","issuer_ticker":"TWST","issuer_name_source":null,"issuer_url":"/issuer/0001219042","owner_cik":null,"owner_name":"ARCH Venture Partners VII, LLC; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Fund VIII Overage, L.P.; BYBEE CLINTON; ARCH Venture Fund VII, L.P.; NELSEN ROBERT","owner_display_name":"ARCH Venture Partners VII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75000.0,"shares_display":"75,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":1050000.0,"total_display":"1,050,000.00","total_whole":"1,050,000","shares_owned_after":954146.0,"shares_owned_after_display":"954,146","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-02","filed_date":"2018-11-06","scope":"insider","n_lines":2},{"id":6062327,"accession":"0000899243-18-009614","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-009614","line_url":"/filing/0000899243-18-009614#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Pulmatrix, Inc.","issuer_ticker":"PULM","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; BYBEE CLINTON; CRANDELL KEITH; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VII, LLC; NELSEN ROBERT; Arch Venture Fund VII LP","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1150000.0,"shares_display":"1,150,000","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":3436456.0,"shares_owned_after_display":"3,436,456","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-04-03","filed_date":"2018-04-05","scope":"insider"},{"id":2084660,"accession":"0001104659-16-131409","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-16-131409","line_url":"/filing/0001104659-16-131409#line-5","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners VII, LLC; ARCH Venture Partners VII, L.P.; BYBEE CLINTON; Arch Venture Fund VII LP; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners VII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":4637137.0,"shares_owned_after_display":"4,637,137","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-06","filed_date":"2016-07-07","scope":"insider"},{"id":2671833,"accession":"0001144204-16-104886","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-16-104886","line_url":"/filing/0001144204-16-104886","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"PHASERX, INC.","issuer_ticker":"PZRX","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; ARCH Venture Partners VII, L.P.; Arch Venture Fund VII LP; BYBEE CLINTON; ARCH Venture Partners VII, LLC; GILLIS STEVEN; NELSEN ROBERT","owner_display_name":"CRANDELL KEITH","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":680059.0,"shares_display":"680,059","price_per_share":0.01,"price_display":"0.01","price_state":"stated","total_value":6800.59,"total_display":"6,800.59","total_whole":"6,801","shares_owned_after":2049378.0,"shares_owned_after_display":"2,049,378","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-23","filed_date":"2016-05-25","scope":"insider","n_lines":2},{"id":2671827,"accession":"0001144204-16-104886","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-104886","line_url":"/filing/0001144204-16-104886#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"PHASERX, INC.","issuer_ticker":"PZRX","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; ARCH Venture Partners VII, L.P.; Arch Venture Fund VII LP; BYBEE CLINTON; ARCH Venture Partners VII, LLC; GILLIS STEVEN; NELSEN ROBERT","owner_display_name":"CRANDELL KEITH","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":2854222.0,"shares_owned_after_display":"2,854,222","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-23","filed_date":"2016-05-25","scope":"insider"},{"id":8885124,"accession":"0001144204-15-037762","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-15-037762","line_url":"/filing/0001144204-15-037762#line-2","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Pulmatrix, Inc.","issuer_ticker":"PULM","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners VII, LLC; Arch Venture Fund VII LP; GILLIS STEVEN; CRANDELL KEITH; ARCH Venture Partners VII, L.P.; NELSEN ROBERT; BYBEE CLINTON","owner_display_name":"ARCH Venture Partners VII, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":72750.0,"shares_display":"72,750","price_per_share":6.875,"price_display":"6.88","price_state":"stated","total_value":500156.25,"total_display":"500,156.25","total_whole":"500,156","shares_owned_after":2286456.0,"shares_owned_after_display":"2,286,456","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-06-16","filed_date":"2015-06-17","scope":"insider"},{"id":6783184,"accession":"0001012975-14-000328","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001012975-14-000328","line_url":"/filing/0001012975-14-000328","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Receptos, Inc.","issuer_ticker":"RCPT","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH VENTURE FUND VI LP; ARCH Venture Partners VII, L.P.; BYBEE CLINTON; Arch Venture Fund VII LP; NELSEN ROBERT; ARCH VENTURE PARTNERS VI LLC; CRANDELL KEITH; ARCH Venture Partners VII, LLC; ARCH VENTURE PARTNERS VI LP","owner_display_name":"ARCH VENTURE FUND VI LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8395.0,"shares_display":"8,395","price_per_share":28.39,"price_display":"28.39","price_state":"stated","total_value":238334.05,"total_display":"238,334.05","total_whole":"238,334","shares_owned_after":2058634.0,"shares_owned_after_display":"2,058,634","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-05-14","filed_date":"2014-05-15","scope":"insider","n_lines":2},{"id":6783174,"accession":"0001012975-14-000328","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001012975-14-000328","line_url":"/filing/0001012975-14-000328","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Receptos, Inc.","issuer_ticker":"RCPT","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH VENTURE FUND VI LP; ARCH Venture Partners VII, L.P.; BYBEE CLINTON; Arch Venture Fund VII LP; NELSEN ROBERT; ARCH VENTURE PARTNERS VI LLC; CRANDELL KEITH; ARCH Venture Partners VII, LLC; ARCH VENTURE PARTNERS VI LP","owner_display_name":"ARCH VENTURE FUND VI LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":36986.0,"shares_display":"36,986","price_per_share":29.94570810576975,"price_display":"29.95","price_state":"stated","total_value":1107571.96,"total_display":"1,107,571.96","total_whole":"1,107,572","shares_owned_after":2066541.0,"shares_owned_after_display":"2,066,541","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-05-13","filed_date":"2014-05-15","scope":"insider","n_lines":4},{"id":5006183,"accession":"0001104659-13-041516","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-13-041516","line_url":"/filing/0001104659-13-041516#line-4","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Receptos, Inc.","issuer_ticker":"RCPT","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"Arch Venture Fund VII LP; ARCH Venture Partners VII, L.P.; ARCH VENTURE FUND VI LP; BYBEE CLINTON; NELSEN ROBERT; ARCH Venture Partners VII, LLC; CRANDELL KEITH; ARCH VENTURE PARTNERS VI LP; ARCH VENTURE PARTNERS VI LLC","owner_display_name":"Arch Venture Fund VII LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":284485.0,"shares_display":"284,485","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":3982790.0,"total_display":"3,982,790.00","total_whole":"3,982,790","shares_owned_after":2101376.0,"shares_owned_after_display":"2,101,376","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-14","filed_date":"2013-05-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001885522","name":"Neumora Therapeutics, Inc.","url":"/issuer/0001885522","role":"Ten percent owner","n_filings":2,"first_seen":"2023-09-20","last_seen":"2025-10-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001555279","name":"908 Devices Inc.","url":"/issuer/0001555279","role":"Ten percent owner","n_filings":1,"first_seen":"2020-12-22","last_seen":"2020-12-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001556263","name":"Syros Pharmaceuticals, Inc.","url":"/issuer/0001556263","role":"Ten percent owner","n_filings":4,"first_seen":"2016-07-07","last_seen":"2019-07-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001581280","name":"Twist Bioscience Corp","url":"/issuer/0001581280","role":"Ten percent owner","n_filings":1,"first_seen":"2018-11-06","last_seen":"2018-11-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001574235","name":"Pulmatrix, Inc.","url":"/issuer/0001574235","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2015-06-17","last_seen":"2018-04-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001429386","name":"PHASERX, INC.","url":"/issuer/0001429386","role":"Ten percent owner","n_filings":1,"first_seen":"2016-05-25","last_seen":"2016-05-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001463729","name":"Receptos, Inc.","url":"/issuer/0001463729","role":"Ten percent owner","n_filings":2,"first_seen":"2013-05-14","last_seen":"2014-05-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001544443","retrieved_at":"2026-08-23T05:05:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}